%0 Journal Article %T Engineering a Brighter Future: The Evolving Role of the Pharmacist in the Era of the HeartMate 3 %A Alana M. Ciolek %A Audrey J. Littlefield %A Douglas L. Jennings %J Annals of Pharmacotherapy %@ 1542-6270 %D 2019 %R 10.1177/1060028018813371 %X Continuous-flow left-ventricular assist devices (CF-LVADs) are an option for patients with end-stage heart failure requiring durable mechanical circulatory support. Two of the older-generation CF-LVADs have been associated with multiple device-related complications, including bleeding and thrombosis. The newest generation CF-LVAD, the HeartMate 3, was engineered specifically to prevent device-related thrombosis. As more data enhance our understanding of the burden of bleeding and thrombotic adverse events, patients with durable mechanical circulatory support may require less-aggressive antithrombotic therapy %K anticoagulation %K HeartMate 3 %K hemocompatibility %K left-ventricular assist device %U https://journals.sagepub.com/doi/full/10.1177/1060028018813371